APHYLINE M
Each uncoated bilayered tablet contains : Acebrophylline 200 mg (As Sustained Release) Montelukast Sodium IP Eq. to Montelukast 10 mg Excipients q.s.
| Composition | Each uncoated bilayered tablet contains : Acebrophylline 200 mg (As Sustained Release) Montelukast Sodium IP Eq. to Montelukast 10 mg Excipients q.s. |
| Packing | ALU ALU - 10*10 |
| MRP | ₹188 |
Product Overview
APHYLINE M is a potent respiratory combination formulated to provide sustained relief from bronchial asthma, COPD, and allergic rhinitis. Combining sustained-release Acebrophylline with Montelukast, it delivers simultaneous bronchodilation, mucolysis, and anti-leukotriene action to keep airways open and clear of sticky mucus. This twice-action bilayered tablet reduces airway inflammation and prevents frequency of asthmatic attacks.
Indications
This bilayered tablet is indicated for:
- Bronchial Asthma: Prophylaxis and chronic management of asthma, including prevention of exercise-induced bronchoconstriction.
- Chronic Obstructive Pulmonary Disease (COPD): Maintenance therapy for airflow obstruction, chronic bronchitis, and emphysema.
- Allergic Rhinitis with Asthma: Comprehensive management of seasonal and perennial allergic symptoms accompanied by lower airway spasm.
- Airway Hyper-responsiveness: Reducing inflammation and mucus hypersecretion in reactive airway disease.
Dosage & Administration
The recommended adult dosage is one tablet once daily, preferably taken in the evening after a meal, or as prescribed by a respiratory physician. Swallow whole with water; do not crush, chew, or break the sustained-release tablet.
Adverse Effects
- Epigastric pain, nausea, or vomiting
- Headache and dizziness
- Diarrhea or dyspepsia
- Restlessness or mild tremors
View Complete Medical Information
Contraindications
Contraindicated in patients with hypersensitivity to Acebrophylline, Montelukast, or xanthine derivatives. Do not administer to patients with acute myocardial infarction, hypotension, hemodynamically unstable cardiac arrhythmias, or severe renal impairment.
Warnings & Precautions
Not intended for relieving acute bronchospasm or asthma attacks; patients must keep a short-acting rescue inhaler available. Use with caution in patients with hepatic dysfunction, hyperthyroidism, hypertension, or a history of seizure disorders. Monitor for neuropsychiatric events associated with montelukast.
Drug Interactions
Acebrophylline clearance may be reduced by CYP450 inhibitors such as erythromycin, ciprofloxacin, cimetidine, and allopurinol, leading to increased plasma levels and potential toxicity. Co-administration with phenytoin, phenobarbital, or rifampicin can decrease the plasma concentration of both active components.
Storage Instructions
Store below 30°C in a dry place, protected from direct moisture and light. Keep out of reach of children.
Request This Product
- WHO-GMP Certified Formulations
- Monopoly Rights Available
- Get bulk pricing & MOQ
+91 9689237122 · replies within hours
Related Products
More products in the COUGH PREPARATION therapeutic category
CICITRI TAB
Each Film Coated Tablet Contains: Cetirizine Dihydrochloride IP 10mg Excipients q.s
BLISTER CLEAR PVC - 10*20
CICOF T SYP 100 ML
Each 5 ml Contains : Terbutaline Sulphate IP 1.25 mg Ambroxol Hydrochloride IP 15 mg Guaiphenesin IP 50 mg Menthol IP 1.5 mg In a Flavoured Syrupy Base q.s.
PET AMBER BOTTLE WITH MEASURING CAP - 100 ML
CICOF DS
Each 5 ml contains Phenylephrine 5mg+ Chlorpheniramine Maleate 2mg+ Dextromethorphan Hydrobromide 15mg
PET AMBER BOTTLE - 100 ML
Interested in this product?
Contact our team to discuss PCD franchise, bulk orders, or contract manufacturing for your market.